71 related articles for article (PubMed ID: 20417872)
1. Derivative (1;18)(q10;q10) in essential thrombocythemia.
Azuma T; Yamanouchi J; Inoue K; Kohno M; Narumi H; Fujiwara H; Yakushijin Y; Hato T; Yasukawa M
Cancer Genet Cytogenet; 2010 May; 199(1):62-4. PubMed ID: 20417872
[TBL] [Abstract][Full Text] [Related]
2. Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation.
Leon A; Staropoli JF; Hernandez JM; Longtine JA; Kuo FC; Dal Cin P
Leuk Res; 2011 Sep; 35(9):1188-92. PubMed ID: 21376394
[TBL] [Abstract][Full Text] [Related]
3. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.
Ohyashiki K; Kodama A; Ohyashiki JH
Cancer Genet Cytogenet; 2008 Oct; 186(1):6-11. PubMed ID: 18786436
[TBL] [Abstract][Full Text] [Related]
4. Essential thrombocythemia with myelofibrosis transformed into acute myeloid leukemia with der(1;15)(q10;q10): case report and literature review.
Charafeddine KM; Mahfouz RA; Zaatari GS; Ibrahim GY; Muwakkit SA; Najm ND; Farra CG
Cancer Genet Cytogenet; 2010 Jul; 200(1):28-33. PubMed ID: 20513531
[TBL] [Abstract][Full Text] [Related]
5. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
Larsen TS; Hasselbalch HC; Pallisgaard N; Kerndrup GB
Cancer Genet Cytogenet; 2007 Jan; 172(2):107-12. PubMed ID: 17213018
[TBL] [Abstract][Full Text] [Related]
6. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
[TBL] [Abstract][Full Text] [Related]
7. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
8. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia.
Hsiao HH; Ito Y; Sashida G; Ohyashiki JH; Ohyashiki K
Leuk Res; 2005 Nov; 29(11):1247-52. PubMed ID: 16164981
[TBL] [Abstract][Full Text] [Related]
9. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
10. Essential thrombocythemia with deleted 5q--a genetic and morphologic hybrid?
Wong KF; Yu PH; Wong WS
Cancer Genet Cytogenet; 2010 Aug; 201(1):39-41. PubMed ID: 20633767
[TBL] [Abstract][Full Text] [Related]
11. Insertion (4;11)(q27;q24q21) in a patient with essential thrombocythemia with progression to myelofibrosis.
Gargallo P; Hagemeijer A; Vassallu P; Kornblihtt L; Heller P; Molinas F; Larripa I
Cancer Genet Cytogenet; 2004 Oct; 154(1):72-6. PubMed ID: 15381377
[TBL] [Abstract][Full Text] [Related]
12. Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia.
Medeiros BC; Zhang T; Lipton JH; Kamel-Reid S
Am J Hematol; 2007 Apr; 82(4):293-4. PubMed ID: 17013813
[TBL] [Abstract][Full Text] [Related]
13. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
[TBL] [Abstract][Full Text] [Related]
14. A der(1;15)(q10;q10) is a rare nonrandom whole-arm translocation in patients with acute lymphoblastic leukemia.
Park TS; Song J; Lee KA; Lee SG; Yoon S; Kim JS; Lyu CJ; Choi JR
Cancer Genet Cytogenet; 2007 Dec; 179(2):132-5. PubMed ID: 18036400
[TBL] [Abstract][Full Text] [Related]
15. [Essential thrombocythemia in transformation to acute leukemia (FAB-M0) as a natural history from myelofibrosis with t(1;7)].
Hayashi S; Iwama H; Uchida Y; Kawakubo K; Inatomi Y; Nagasu M; Miyazawa K; Ohyashiki JH; Ohyashiki K; Toyama K
Rinsho Ketsueki; 1997 May; 38(5):445-7. PubMed ID: 9194391
[TBL] [Abstract][Full Text] [Related]
16. The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia.
Lambert JR; Gale RE; Linch DC
Br J Haematol; 2009 Apr; 145(1):128-30. PubMed ID: 19222478
[TBL] [Abstract][Full Text] [Related]
17. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
Poodt J; Fijnheer R; Walsh IB; Hermans MH
Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
[TBL] [Abstract][Full Text] [Related]
18. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic findings in untreated patients with essential thrombocythemia.
Panani AD
In Vivo; 2006; 20(3):381-4. PubMed ID: 16724675
[TBL] [Abstract][Full Text] [Related]
20. Derivative (1;18)(q10;q10): a recurrent and novel unbalanced translocation involving 1q in myeloid disorders.
Wan TS; Ma SK; Au WY; Chan LC
Cancer Genet Cytogenet; 2001 Jul; 128(1):35-8. PubMed ID: 11454427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
